ESMO 2019 - Amgen’s KRAS drug finds colorectal cancer a chal...

Amgen’s KRAS inhibitor AMG 510 has shown little effect in colorectal cancer patients, according to new data reported at the

As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian...

Merck KGaA's bold new approach to cancer immunotherapy

Germany’s Merck KGaA is hoping to stand out from the crowd with a bold new approach to cancer immunotherapy.

ESMO round-up: Big win for AstraZeneca in ovarian cancer, an...

Several drugmakers announced significant trial findings at this week’s European Society for Medical Oncology (ESMO) conference in Munich.

Tagrisso on target to be EGFR+ lung cancer standard

New phase 3 data presented at ESMO earlier today suggests Tagrisso could be a major step forward in treating patients with EGFR positive non-small cell lung cancer.

Rubraca outshines rivals in ovarian cancer maintenance thera...

Clovis' Rubraca, the drug showing significant benefits for all ovarian cancer patients in a maintenance setting – and better results than its rivals.